Source: CureToday articles
The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.
Recent Content
- Research Identifies Need for Increased Evidence-Based Use of Buspirone
- A Healer’s Touch During My Experience With Cancer Care
- Single Dose of Xofluza Reduces Odds of Untreated Household Members Contracting Influenza
- Ferritin-NP-preS1 Therapeutic Vaccine With siRNA Shows Durable Effects in CHB
- Medically Integrated Pharmacies: The Role of Limited Distribution Networks in Advancing Modern Oncology Pharmacy
- Community Oncology Faces Crossroads Under the Inflation Reduction Act
- The Calm of Unbroken Kindness
- Breaking Down the Benefits of Clinical Trial Participation in Cancer Care
- Measles Update: The Public’s View and How Pharmacists Can Combat Misinformation
- Smoking Data May Guide Improved Lung Cancer Care and Patient Support